We’re excited to introduce our new integrated drug discovery service, A-Booster. What is A-Booster? A-Booster is a data-driven drug discovery solution designed to shorten the time to candidate generation.

Your Strategic Benefits
With A-Booster, you save time and resources using pre-qualified compounds, proprietary datasets, and validated assay systems. You can expand your pipeline by unlocking opportunities from our 1,000 pharma-originated legacy projects—while retaining full ownership of co-created IP.

Why We Can Accelerate Your Projects
We help you skip early stages and move faster — jump-starting from pre-qualified hits or leads and leveraging proprietary pharma-grade assets to shorten the path to value.

How We Accelerate Your Projects
Our AI-powered, high-speed LG/LO engine is driven by three pillars: AI tools trained on legacy data, an optimized automated research process, and the pharma-proven expert intuition. From initial Hit to Candidate, we run a continuous DMTA cycle—Design, Make, Test, Analysis—to keep decisions fast and data-driven. AI and in-silico generative models, advanced synthetic chemistry, rapid HT-ADMET turnaround, and data-driven insight enable rapid, successful discovery—compressing timelines to less than 18 months from hit to candidate.

Proven Track Record
In real programs, clients reach milestones faster—as little as six months to identify promising leads, and around one year to nominate candidates—through AI-powered DMTA and data-driven optimization.

We’re ready to partner with you. Share your disease area, target class, or specific targets. Our team will review relevant legacy projects and respond within two to three business days. We will tailor a drug candidate generation strategy for you.